MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

▤ Summary

MiNK Therapeutics announced that the first patient has been dosed in its randomized Phase 2 trial of agenT-797 for acute lung injury and critical illness. The study is testing the therapy plus standard of care against placebo plus standard of care in patients who meet Global ARDS criteria. MiNK says the trial is now active in Ukraine and will also expand to U.S. sites under an active IND. The company expects preliminary data in the second half of 2026 and positions agenT-797 as an off-the-shelf immune therapy for severe respiratory failure.

▦ Linked Companies